BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Intellikine, Inc. 

10931 N. Torrey Pines Road
Suite 103
San Diego  California  92037  U.S.A.
Phone: 858-768-6500 Fax:


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) to Acquire Privately-held Intellikine, Inc. for Up to $310 Million Cash 12/21/2011 6:04:59 AM    More...
Intellikine, Inc. Earns $4 Million in Milestone Payments for Initiation of Two Phase 1 Clinical Trials for IPI-145, a Potent Inhibitor of PI3Kdelta and PI3Kgamma 10/31/2011 8:38:28 AM    More...
Intellikine, Inc. Initiates Phase I Study of Targeted Cancer Therapeutic INK1117 10/12/2011 9:55:31 AM    More...
Intellikine, Inc., a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk Chief Medical Officer 7/12/2011 8:38:02 AM    More...
Intellikine, Inc. and the PKD Foundation Collaborate to Advance Next-Generation Therapies for Polycystic Kidney Disease 2/10/2011 9:17:41 AM    More...
Intellikine, Inc. and the Multiple Myeloma Research Consortium Initiate Phase I Trial of Targeted Drug INK128 11/30/2010 9:09:37 AM    More...
Numerate and Intellikine, Inc. Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha 8/11/2010 9:03:33 AM    More...
Infinity Pharmaceuticals Inc. (INFI) and Intellikine, Inc. Enter Agreement to Develop Oral Therapies Targeting PI3 Kinase Delta, Gamma; Intellikine To Receive $13.5 Million Initially In Deal Valued Up to $488 Million 7/8/2010 7:14:25 AM    More...
Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million Each to Intellikine, Inc. and Tragara Pharmaceuticals, Inc. to Advance Next-Generation Therapies for Multiple Myeloma 3/29/2010 1:07:43 PM    More...
Intellikine, Inc. Appoints William Rohn to its Board of Directors 2/23/2010 8:21:07 AM    More...
12